TY - JOUR
T1 - Age of onset of cerebral venous thrombosis
T2 - the BEAST study
AU - Ranjan, Redoy
AU - Ken-Dror, Gie
AU - Martinelli, Ida
AU - Grandone, Elvira
AU - Hiltunen, Sini
AU - Lindgren, Erik
AU - Margaglione, Maurizio
AU - le Cam Duchez, Veronique
AU - Bagan Triquenot, Aude
AU - Zedde, Marialuisa
AU - Mancuso, Michelangelo
AU - Ruigrok, Ynte M.
AU - Worrall, Brad
AU - Majersik, Jennifer J.
AU - Putaala, Jukka
AU - Haapaniemi, Elena
AU - Zuurbier, Susanna M.
AU - Brouwer, Matthijs C.
AU - Passamonti, Serena M.
AU - Abbattista, Maria
AU - Bucciarelli, Paolo
AU - Lemmens, Robin
AU - Pappalardo, Emanuela
AU - Costa, Paolo
AU - Colombi, Marina
AU - Aguiar de Sousa, Diana
AU - Rodrigues, Sofia
AU - Canhao, Patrícia
AU - Tkach, Aleksander
AU - Santacroce, Rosa
AU - Favuzzi, Giovanni
AU - Arauz, Antonio
AU - Colaizzo, Donatella
AU - Spengos, Kostas
AU - Hodge, Amanda
AU - Ditta, Reina
AU - Han, Thang S.
AU - Pezzini, Alessandro
AU - Coutinho, Jonathan M.
AU - Thijs, Vincent
AU - Jood, Katarina
AU - Tatlisumak, Turgut
AU - Ferro, José M.
AU - Sharma, Pankaj
N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants awarded to P.S. from the Stroke Association (UK) and the Dowager Countess Eleanor Peel Trust (UK). P.S. was funded by a Department of Health (UK) Senior Fellowship at Imperial College London for part of this study. The cohort of 231 French cases was constituted during a hospital protocol of clinical research approved by the French Ministry of Health; the biological collection was kept and managed by INSERM CIC-CRB 1404, F-76000 Rouen, France. The controls from Belgium were genotyped as part of the SIGN study. R.L. is a senior clinical investigator of FWO Flanders. T.T. is the recipient of funding from the Sigrid Juselius Foundation (Finland), Helsinki University Central Hospital (Finland), Sahlgrenska University Hospital (Sweden) and the University of Gothenburg (Sweden). The Swedish Research Council (2018-02543) and the Swedish Heart and Lung Foundation (20190203) also supported the study. J.M.C. has received funding from the Dutch Thrombosis Foundation. This material results from work supported by resources and the use of facilities at the VA Maryland Health Care System, Baltimore, Maryland, and was also supported in part by the National Institutes of Health (U01NS069208, R01NS105150 and R01NS100178). Publisher Copyright: © European Stroke Organisation 2023.
PY - 2023/3
Y1 - 2023/3
N2 - Background: Cerebral venous thrombosis (CVT) is an uncommon cause of stroke in young adults. We aimed to determine the impact of age, gender and risk factors (including sex-specific) on CVT onset. Methods: We used data from the BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis), a multicentre multinational prospective observational study on CVT. Composite factors analysis (CFA) was performed to determine the impact on the age of CVT onset in males and females. Results: A total of 1309 CVT patients (75.3% females) aged ⩾18 years were recruited. The overall median (IQR-interquartile range) age for males and females was 46 (35–58) years and 37 (28–47) years (p < 0.001), respectively. However, the presence of antibiotic-requiring sepsis (p = 0.03, 95% CI 27–47 years) among males and gender-specific risk factors like pregnancy (p < 0.001, 95% CI 29–34 years), puerperium (p < 0.001, 95% CI 26–34 years) and oral contraceptive use (p < 0.001, 95% CI 33–36 years) were significantly associated with earlier onset of CVT among females. CFA demonstrated a significantly earlier onset of CVT in females, ~12 years younger, in those with multiple (⩾1) compared to ‘0’ risk factors (p < 0.001, 95% CI 32–35 years). Conclusions: Women suffer CVT 9 years earlier in comparison to men. Female patients with multiple (⩾1) risk factors suffer CVT ~12 years earlier compared to those with no identifiable risk factors.
AB - Background: Cerebral venous thrombosis (CVT) is an uncommon cause of stroke in young adults. We aimed to determine the impact of age, gender and risk factors (including sex-specific) on CVT onset. Methods: We used data from the BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis), a multicentre multinational prospective observational study on CVT. Composite factors analysis (CFA) was performed to determine the impact on the age of CVT onset in males and females. Results: A total of 1309 CVT patients (75.3% females) aged ⩾18 years were recruited. The overall median (IQR-interquartile range) age for males and females was 46 (35–58) years and 37 (28–47) years (p < 0.001), respectively. However, the presence of antibiotic-requiring sepsis (p = 0.03, 95% CI 27–47 years) among males and gender-specific risk factors like pregnancy (p < 0.001, 95% CI 29–34 years), puerperium (p < 0.001, 95% CI 26–34 years) and oral contraceptive use (p < 0.001, 95% CI 33–36 years) were significantly associated with earlier onset of CVT among females. CFA demonstrated a significantly earlier onset of CVT in females, ~12 years younger, in those with multiple (⩾1) compared to ‘0’ risk factors (p < 0.001, 95% CI 32–35 years). Conclusions: Women suffer CVT 9 years earlier in comparison to men. Female patients with multiple (⩾1) risk factors suffer CVT ~12 years earlier compared to those with no identifiable risk factors.
KW - Cerebral venous thrombosis
KW - age of onset
KW - cerebral venous sinus thrombosis
KW - women
UR - http://www.scopus.com/inward/record.url?scp=85146097582&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/23969873221148267
DO - https://doi.org/10.1177/23969873221148267
M3 - Article
C2 - 37021156
SN - 2396-9873
VL - 8
SP - 344
EP - 350
JO - European Stroke Journal
JF - European Stroke Journal
IS - 1
ER -